GSK suing Pfizer, BioNTech over COVID-19 vaccines patents
Seeking Alpha News (Thu, 25-Apr 10:56 AM ET)
GSK sues Pfizer, BioNTech over COVID-19 vaccines patents
Seeking Alpha News (Thu, 25-Apr 10:56 AM ET)
GSK’s Jemperli Awaits FDA Expansion Approval
TipRanks (Wed, 24-Apr 7:57 AM ET)
Sanofi reportedly lining up banks for consumer products spinoff
Seeking Alpha News (Tue, 23-Apr 1:32 PM ET)
Sanofi reportedly settles 4K Zantac cases for $100M
Seeking Alpha News (Mon, 22-Apr 12:03 PM ET)
WuXi Biologics Reports Solid 2023 Annual Results
PRNewswire (Tue, 26-Mar 9:53 AM ET)
Business Wire (Sat, 16-Mar 8:00 AM ET)
Globe Newswire (Tue, 12-Mar 10:20 AM ET)
Business Wire (Thu, 7-Mar 12:00 PM ET)
Business Wire (Wed, 14-Feb 8:00 AM ET)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
GSK PLC American Depositary Shares (Each Representing Two Ordinary Shares) trades on the NYSE stock market under the symbol GSK.
As of April 25, 2024, GSK stock price climbed to $40.88 with 1,185,305 million shares trading.
GSK has a beta of 0.32, meaning it tends to be less sensitive to market movements. GSK has a correlation of 0.05 to the broad based SPY ETF.
GSK has a market cap of $83.52 billion. This is considered a Large Cap stock.
Last quarter GSK PLC American Depositary Shares (Each Representing Two Ordinary Shares) reported $10 billion in Revenue and $.72 earnings per share. This beat revenue expectation by $455 million and missed earnings estimates by -$.03.
In the last 3 years, GSK stock traded as high as $46.97 and as low as $28.47.
The top ETF exchange traded funds that GSK belongs to (by Net Assets): GCOW, PPH, AVDE, RODM, FENI.
GSK stock has underperformed the market in the last year with a return of +15.5%, while SPY returned +23.1%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in GSK shares. However, GSK has outperformed the market in the last 3 month and 2 week periods, returning +5.8% and +0.5%, while SPY returned +3.6% and -2.5%, respectively. This indicates GSK has been having a stronger performance recently.
GSK support price is $40.42 and resistance is $41.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GSK stock will trade within this expected range on the day.